Dr. Amlan Basu will join Montreux Capital Management (UK) as its new Chief Medical Officer in a move that is expected to bring a breadth of clinical expertise to the investment group. Dr. Basu, who trained at University College London and the Maudsley, has held many prominent posts across his career, including Clinical Director at Broadmoor Hospital. He will bring a wealth of expertise to the business, working with the existing portfolio on clinical and medical oversight but also assessing new target acquisitions from a clinical perspective, adding another dimension to the rigorous approach taken by Montreux’s investment advisory team. 

Across a prestigious career, Dr. Basu was most recently Chief Medical Officer for one of the Montreux Healthcare Fund’s (the “Fund”) portfolio businesses. He held an honorary post at the Institute of Psychiatry, Psychology and Neuroscience at King’s College London for over 17 years, publishing several research papers in the fields of genetics, psychopharmacology and service development. He is also a Fellow of the Royal College of Psychiatrists.

On his appointment to Montreux Capital Management (UK)  Dr. Basu stated: “I am extremely pleased to be joining Montreux and hope to add significantly to the team, building on its solid record within the specialist care space.”

Oliver Harris, CEO, Montreux Capital Management (UK) stated: “Amlan will be a good addition to our team, adding some key skills in areas the business must bolster as we grow. Having worked with Amlan for a while within the Fund’s portfolio businesses, I can attest to his work ethic. He will ably supplement the team’s acquisition plans for the Fund and their ongoing work within the portfolio businesses. We look forward to working with him.”

Find Us

Thameside House
Hurst Road
East Molesey

T: + 44 (0) 1932 860 140
E: info@montreuxcm.com

Information on this webpage relates to and is provided by Montreux Capital Management (UK) Limited

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Montreux Capital Management (UK) Limited and Sapia Partners LLP (together “the Sponsors,” or “Sponsor”) do not provide specific individual advice on the suitability of investments with regard to a potential investor’s individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.

Montreux Capital Management (UK) Limited is an Appointed Representative of Sapia Partners LLP which is authorised and regulated by the Financial Conduct Authority.